PGE2 Levels in Patient Treated With NSAIDs

Status Completed

Clinical Trial Summary

The aim of this study is to determine vitreous levels of nonsteroidal antinflammatory drugs (NSAIDs) and prostaglandinE2 (PGE2) in eyes scheduled for vitrectomy.

All patients received the study drugs for 3 days before surgery. 0.5 to 1.0 mL of undiluted vitreous was removed using the vitreous cutter positioned in the midvitreous cavity. Samples were immediately frozen and stored at −80°C until analysis.

Sample analyses were performed using an high-performance liquid chromatography system. The lower limit of quantitation was 0.8 ng/mL.

PGE2 levels were analyzed using the Prostaglandin E2 Monoclonal EIA Kit (Cayman Chemical Company) according to the manufacturer's instructions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03597867
Study type	Interventional
Source	University of Trieste
Contact
Status	Completed
Phase	Phase 3
Start date	April 25, 2018
Completion date	July 9, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Not yet recruiting	`NCT05248139` - Safety and Effectiveness of Drop-free Small Incision Cataract Surgery	N/A
Terminated	`NCT01214174` - Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients	Phase 2
Completed	`NCT03332342` - Closed Eye Neutrophils in Dry Eye Disease	N/A
Completed	`NCT02128113` - RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD	Phase 2
Completed	`NCT01808547` - Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects	Phase 3
Active, not recruiting	`NCT04374656` - Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
Recruiting	`NCT05668455` - Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)	Phase 3
Completed	`NCT00645671` - Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery	Phase 3
Completed	`NCT00789971` - Triamcinolone Versus Topical Treatment in Post Operative Phacoemulsification	N/A
Completed	`NCT02786901` - LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery	Phase 3
Completed	`NCT00699153` - Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery	Phase 3
Terminated	`NCT03596723` - KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children	Phase 3
Completed	`NCT01576952` - Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects	Phase 3
Withdrawn	`NCT03408015` - Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease	Phase 4
Completed	`NCT03580473` - Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification	Phase 2
Completed	`NCT04812951` - Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery	Early Phase 1
Completed	`NCT03302273` - Corneal Epithelial Stem Cells and Dry Eye Disease	N/A
Completed	`NCT04690829` - Biomarkers in Ocular Inflammation and Uveitis
Withdrawn	`NCT01721694` - Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection	Phase 3